Navigation Links
Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Date:3/6/2013

CARLSBAD, Calif., March 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 2:00 p.m. ET in Miami, FL.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an a
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
2. Tarix Pharmaceuticals Peptide Technology Stimulates Revascularization Following Ischemia
3. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
4. TauRx Pharmaceuticals Receives $10.5m Follow-On Investment from Dundee Corporation
5. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
6. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
7. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
8. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
9. AVANIR Pharmaceuticals To paticipate in two conferences in March
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
11. Adamis Pharmaceuticals Prevails in License Dispute Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world ... and restore failing hearts, said today it will participate ... Conference on Tuesday, June 9. D. ... provide an update on the company, beginning at 2:00 ... The presentation will be available through the ...
(Date:5/26/2015)... , England and PITTSBURGH , May 26, ... leading global pharmaceutical company, today announced that Mylan CEO ... Bernstein Strategic Decisions Conference, Friday, May 29, 2015 at ... access a live webcast of the presentation via the ... . An archived version will also be available following ...
(Date:5/26/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("the ... therapeutics that address unmet medical needs in women,s ... will present at the Marcum MicroCap Conference ... 4:00 PM EDTLocation: , The Grand Hyatt, New ... under  ,Investor, or  click here The ...
Breaking Medicine Technology:Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast 2Juniper Pharmaceuticals to Present at Investor Conference on May 28, 2015 2
... VANCOUVER, British Columbia, Sept. 19, 2011 ... the company has successfully completed an amendment to the approved ... expand the inclusion criteria for the Prostate Cancer SATURN Clinical ... drug custirsen, also known as OGX-011/TV-1011, can improve quality of ...
... has announced the acquisition of MediaDent ® , a ... Dental Imaging solution. MediaDent is the flagship product of ... new division of SuccessEHS. The addition of MediaDent will ... Health Record (EHR) and Practice Management solution with ...
Cached Medicine Technology:OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial 2OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial 3OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial 4SuccessEHS Announces Acquisition of MediaDent® Electronic Dental Record 2SuccessEHS Announces Acquisition of MediaDent® Electronic Dental Record 3SuccessEHS Announces Acquisition of MediaDent® Electronic Dental Record 4
(Date:5/26/2015)... Platte, LA (PRWEB) May 26, 2015 ... readers along with her as she writes an unforgettable ... difficult challenges in her life. The first black student ... was harassed and beaten by some students, treated harshly ... white woman. A motivating personal phone conversation with Dr. ...
(Date:5/26/2015)... The federal court overseeing more than ... of individuals who were allegedly injured by the medication ... Day. According to an Order issued in the U.S. ... topics to be addressed include Xarelto adverse events, clinical ... test based testing with Xarelto, and Xarelto pharmacology. All ...
(Date:5/26/2015)... NM (PRWEB) May 26, 2015 ... providing New Mexico patients with MRI, Ultrasound, and ... by the American College of Radiology. The center ... CT services. , In order to be ... a variety of qualifications including personnel qualifications, adequacy ...
(Date:5/26/2015)... 2015 Surging to over 674,923 of ... leading online health and wellness sites, Consumer Health Digest ... community. It has proven to be a reliable ... watch videos, ask questions and interact with the online ... official Consumer Health Digest YouTube Channel has offered a ...
(Date:5/26/2015)... 3,000 senior industry executives are expected ... the future of the connected car. A very special ... that can read a driver’s brain waves. Visitors to ... simulator by mind alone just by gripping the steering ... “We are working on cognitive load, altering music based ...
Breaking Medicine News(10 mins):Health News:Grace Sibley Releases Second Book, God's Unstoppable Favor 2Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 2Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 3Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 4Health News:Consumer Health Digest Official YouTube Channel: A Reliable Source of Health Information 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 3
... reduce up to 70 percent of spina bifida cases, according ... which the neural tube (an embryonic form of the brain ... condition that involves lifelong medical management. It is also one ... show that folic acid supplementation around the time of conception ...
... of drugs prescribed to children with depression may have ... a new study. Researchers say they found a reduction ... more commonly known as Prozac. Fluoxetine is the only ... and adolescents. ,Other preliminary studies show the use ...
... more use to humans than just for honey find researchers ... of bee venom was given to rats with advanced rheumatoid ... swelling on affected paws. ,Researchers then examined the effects ... obtained from human patients. The venom blocked the expression of ...
... now say they’ve found one drug that may successfully treat ... 22 patients with breast, prostate, lung, ovarian, colon and pancreatic ... by more than 50 percent. Specialists say , it turns ... stop it from growing, and so there’s much less side ...
... shows that gaining 15 pounds or more over several years puts ... are obese but maintain a stable weight . ,Researchers ... years. Most participants gained 15 pounds or more during the study, ... problems such as heart disease, stroke and diabetes. But only 4 ...
... infection can now be virtually eliminated by a one-time ... a recent study . Researchers studied a community in ... At the beginning of the study, nearly 10 percent ... causes repeated symptoms that can eventually lead to scarring ...
Cached Medicine News:
... transmitted through sorted fiberglass bundles ... transmit it to a user's ... designed for rough, industrial handling ... low cost if they should ...
The original Zeppelin High-Speed Motordrill System has been developed to rapidly cut bone, plastic and metal with utmost precision. 120-150 psi - 90.000 rpm - 90g - autoclavable at <134 C....
... is a high speed pneumatic ... dissection of bone, biometals, bioplastics ... not only provides speed 80,000 ... the control and precision that ...
Legend Gold is the most powerful of the new motors. It runs at an impressive 76,000 rpm at 120 psi/8 bar. It is also smaller than the Midas Rex Classic motor, with an enhanced ergonomic design....
Medicine Products: